Daniel Ceballos

Las Palmas De Gran Canaria, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Journal: Alimentary pharmacology & therapeutics

Published: March 28, 2026

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Journal: Alimentary pharmacology & therapeutics

Published: March 14, 2026

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.

Journal: United European gastroenterology journal

Published: February 01, 2026

Sweet legacy, bitter outcomes: sugar, sweeteners, and the microbial origins of a modern syndrome. An evidence-based narrative review.

Sweet legacy, bitter outcomes: sugar, sweeteners, and the microbial origins of a modern syndrome. An evidence-based narrative review.

Journal: Revista espanola de enfermedades digestivas

Published: January 22, 2026

Healthcare professionals' experience with oral oligomeric supplements in malnourished patients in Spain: S-QUEST Study.

Healthcare professionals' experience with oral oligomeric supplements in malnourished patients in Spain: S-QUEST Study.

Journal: Revista espanola de enfermedades digestivas

Published: December 18, 2025

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Journal: Journal of Crohn's & colitis

Published: October 09, 2025

Digestive disease in individuals living with obesity: beyond weight loss.

Digestive disease in individuals living with obesity: beyond weight loss.

Journal: Revista espanola de enfermedades digestivas

Published: June 27, 2025

Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.

Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.

Journal: Frontiers in cellular and infection microbiology

Published: March 18, 2025

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Journal: Alimentary pharmacology & therapeutics

Published: January 14, 2025

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.

Journal: Gut

Published: August 02, 2024

Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations.

Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations.

Journal: Crohn's & colitis 360

Published: July 31, 2024

Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

Journal: Alimentary pharmacology & therapeutics

Published: June 09, 2024

Showing 1-12 of 33

Last Updated: 09/26/2026